LT Foods Board Approves Interim Dividend and Internal Auditor Changes

LT Foods’ Board of Directors has approved a second interim dividend of ₹1 per share for the financial year 2025-26, with a record date set for February 2, 2026. The board also approved changes to its internal auditors, including the resignation of Protiviti India Member Private Limited and the appointment of Neha Sharma, effective January 28, 2026.

Interim Dividend Declared

The Board of Directors has declared a second interim dividend of ₹1 per equity share with a face value of ₹1 each for the financial year 2025-26. The record date for determining shareholders eligible for the dividend is February 2, 2026. Payment will be made within 30 days of the declaration date.

Internal Auditor Resignation

Protiviti India Member Private Limited has resigned as the internal auditors, effective January 27, 2026, due to pre-occupation and other commitments.

New Internal Auditor Appointed

Neha Sharma has been appointed as the new Internal Auditor, effective January 28, 2026, until the end of financial year 2026-27. The appointment is based on the recommendation of the Audit Committee and aligns with Section 138 of the Companies Act, 2013, and related rules.

Financial Performance: Q3 2026

LT Foods reported consolidated revenue from operations of ₹2,80,920.11 lakhs for Q3 2026, compared to ₹2,27,481.19 lakhs for Q3 2025. The company’s profit before tax stood at ₹22,036.72 lakhs for the quarter, against ₹19,783.95 lakhs in the corresponding quarter of the previous year. Total profit for the period was ₹15,735.21 lakhs.

Nine-Month Performance

For the nine months ended December 31, 2025, LT Foods’ consolidated revenue from operations reached ₹8,03,885.31 lakhs, with a total profit for the period amounting to ₹48,971.04 lakhs.

Standalone Results

The company’s standalone revenue from operations for Q3 2026 was ₹1,06,263.06 lakhs, with a total profit for the period of ₹6,616.87 lakhs.

Source: BSE

Previous Article

Lodha Achieves Best-Ever Quarterly Pre-Sales of INR 56.2 Billion in Q3

Next Article

Max Healthcare Board to Consider Financial Results on February 5, 2026